Lv3
328 积分 2023-05-03 加入
Clinical efficacy of PARP inhibitors in breast cancer
2小时前
已完结
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
1天前
已完结
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
1天前
已完结
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
1天前
已完结
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer
1天前
已完结
The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer
8天前
已完结
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
10天前
已完结
An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study
13天前
已完结
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
16天前
已完结
Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines
23天前
已完结
皖公网安备34019202002308
